PrEP Archives -

FDA okays ViiV’s Apretude as first injectable for HIV PrEP

Phil Taylor Apretude, cabotegravir, Descovy, Gilead Sciences, GlaxoSmithKline, HIV, PrEP, Truvada, ViiV Healthcare 0 Comment

GlaxoSmithKline’ majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir

FDA okays ViiV’s Apretude as first injectable for HIV PrEP

https://pharmaphorum.com/news/fda-okays-viivs-apretude-as-first-injectable-for-hiv-prep/

Digital/ News/ News

Digital pill tracks HIV PrEP adherence with 98% accuracy

Phil Taylor digital, digital health, digital pill, Gilead Sciences, HIV, PrEP, Truvada 0 Comment

A digital pill that records when it is taken has been shown to be highly effective at helping

Digital pill tracks HIV PrEP adherence with 98% accuracy

https://pharmaphorum.com/news/digital-pill-tracks-hiv-prep-adherence-with-98-accuracy/

News/ News/ R&D

Merck halts more trials of HIV candidate islatravir

Phil Taylor antiviral, Gilead Sciences, HIV, infectious disease, Janssen, Merck & Co, PrEP, ViiV Healthcare 0 Comment

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug

Merck halts more trials of HIV candidate islatravir

https://pharmaphorum.com/news/merck-halts-more-trials-of-hiv-candidate-islatravir/

News/ News/ R&D

Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir

Phil Taylor Gilead Sciences, HIV, infectious disease, lenacapavir, PrEP 0 Comment

Gilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug

Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir

https://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/

News

Gilead’s Descovy approved in HIV prophylaxis

Richard Staines Gilead, HIV, PrEP 0 Comment

The FDA has approved Gilead’s combination drug Descovy for HIV prophylaxis in the US, offering a way of

Gilead’s Descovy approved in HIV prophylaxis

https://pharmaphorum.com/news/gileads-descovy-approved-in-hiv-prophylaxis/

Market Access/ News/ News

Gilead will challenge US government patent on PrEP drug Truvada

Phil Taylor Gilead Sciences, HIV, patent litigation, PrEP, Truvada 0 Comment

Gilead Sciences has said it plans to challenge patents held by the US government on the use of

Gilead will challenge US government patent on PrEP drug Truvada

https://pharmaphorum.com/news/gilead-will-challenge-us-government-patent-on-prep-drug-truvada/

Market Access/ News/ News/ News/ Patients/ Top stories

Gilead’s Descovy gets FDA panel OK for PrEP, but not for women

Phil Taylor Descovy, Gilead Sciences, HIV, PrEP 0 Comment

Gilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday –

Gilead’s Descovy gets FDA panel OK for PrEP, but not for women

https://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/

Market Access/ News/ News

FDA reviewer backs Gilead’s Descovy for PrEP, but not in women

Phil Taylor anti-infectives, Descovy, Gilead Sciences, HIV, PrEP 0 Comment

Gilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory

FDA reviewer backs Gilead’s Descovy for PrEP, but not in women

https://pharmaphorum.com/news/fda-reviewer-backs-gileads-descovy-for-prep-but-not-in-women/

Market Access/ News/ News

MPs call for NHS funding for HIV prevention drug

Richard Staines AIDS, HIV, PrEP 0 Comment

Leading UK politicians have called for an HIV prevention drug to be made available across the NHS, after

MPs call for NHS funding for HIV prevention drug

https://pharmaphorum.com/news/mps-call-for-nhs-funding-for-hiv-truvada/

Trending

PrEP

Login